TEETH INTO NASH NEXT?
Still ‘galectin’ CKD data, La Jolla considers oral form; shares roar
By Randy Osborne
Tuesday, March 11, 2014
The higher-dose glitch in otherwise strong phase II results with its galectin-3-targeting chronic kidney disease (CKD) therapy did little to hold back shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC), which closed Tuesday at $17.96, up $7.06, or 64.8 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.